{"id":"https://openalex.org/W1994898376","doi":"https://doi.org/10.1016/j.tips.2013.03.002","title":"The case for soluble A\u03b2 oligomers as a drug target in Alzheimer's disease","display_name":"The case for soluble A\u03b2 oligomers as a drug target in Alzheimer's disease","publication_year":2013,"publication_date":"2013-04-10","ids":{"openalex":"https://openalex.org/W1994898376","doi":"https://doi.org/10.1016/j.tips.2013.03.002","mag":"1994898376","pmid":"https://pubmed.ncbi.nlm.nih.gov/23582316"},"language":"en","primary_location":{"id":"doi:10.1016/j.tips.2013.03.002","doi":"https://doi.org/10.1016/j.tips.2013.03.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.tips.2013.03.002","pdf_url":null,"source":{"id":"https://openalex.org/S31167473","display_name":"Trends in Pharmacological Sciences","issn_l":"0165-6147","issn":["0165-6147","1873-3735"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in Pharmacological Sciences","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054270816","display_name":"Franz F. Hefti","orcid":"https://orcid.org/0000-0002-1177-2714","observed_orcids":["https://orcid.org/0000-0002-1177-2714"]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Franz Hefti","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA. fhefti@acumenpharm.com","Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA. fhefti@acumenpharm.com","institution_ids":["https://openalex.org/I4210160595"]},{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078101395","display_name":"William F. Goure","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William F. Goure","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079115898","display_name":"Jasna Jerec\u0131\u0300\u0107","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jasna Jerecic","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111601961","display_name":"Kent S. Iverson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kent S. Iverson","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041163981","display_name":"Patricia Ann Walicke","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia A. Walicke","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5081926493","display_name":"Grant A. Krafft","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210160595","display_name":"Acumen Pharmaceuticals (United States)","ror":"https://ror.org/05pvq8q22","country_code":"US","type":"company","lineage":["https://openalex.org/I4210160595"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Grant A. Krafft","raw_affiliation_strings":["Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Acumen Pharmaceuticals Inc., 4435 North First St, Livermore, CA 94551, USA","institution_ids":["https://openalex.org/I4210160595"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5054270816"],"corresponding_institution_ids":["https://openalex.org/I4210160595"],"apc_list":{"value":7030,"currency":"USD","value_usd":7030},"apc_paid":null,"fwci":1.4054,"has_fulltext":false,"cited_by_count":121,"citation_normalized_percentile":{"value":0.81296144,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"34","issue":"5","first_page":"261","last_page":"266"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/soluble-amyloid-beta-oligomers","display_name":"soluble amyloid-beta oligomers","score":0.8960000276565552},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9810000061988831},{"id":"https://openalex.org/keywords/therapeutic-target","display_name":"therapeutic target","score":0.7179999947547913},{"id":"https://openalex.org/keywords/amyloid-plaques","display_name":"amyloid plaques","score":0.6710000038146973},{"id":"https://openalex.org/keywords/synaptic-dysfunction","display_name":"synaptic dysfunction","score":0.6790000200271606},{"id":"https://openalex.org/keywords/memory-impairment","display_name":"memory impairment","score":0.7609999775886536},{"id":"https://openalex.org/keywords/solanezumab","display_name":"solanezumab","score":0.8859999775886536},{"id":"https://openalex.org/keywords/bapineuzumab","display_name":"bapineuzumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/receptor-antagonists","display_name":"receptor antagonists","score":0.9829999804496765},{"id":"https://openalex.org/keywords/disease-modification","display_name":"disease modification","score":0.7160000205039978},{"id":"https://openalex.org/keywords/clinical-drug-development","display_name":"clinical development","score":0.7559999823570251}],"concepts":[{"id":"https://openalex.org/C2780642029","wikidata":"https://www.wikidata.org/wiki/Q726004","display_name":"Oligomer","level":2,"score":0.6575822234153748},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.6369037628173828},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.5214521288871765},{"id":"https://openalex.org/C2777633098","wikidata":"https://www.wikidata.org/wiki/Q2736051","display_name":"Amyloid (mycology)","level":2,"score":0.49335041642189026},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.47896912693977356},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.44767606258392334},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4372294843196869},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4330137372016907},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3548635244369507},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.30438387393951416},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3033076524734497},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28381532430648804},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.1545964777469635},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016229","descriptor_name":"Amyloid beta-Peptides","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.tips.2013.03.002","doi":"https://doi.org/10.1016/j.tips.2013.03.002","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.tips.2013.03.002","pdf_url":null,"source":{"id":"https://openalex.org/S31167473","display_name":"Trends in Pharmacological Sciences","issn_l":"0165-6147","issn":["0165-6147","1873-3735"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in Pharmacological Sciences","raw_type":"journal-article"},{"id":"pmid:23582316","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23582316","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Trends in pharmacological sciences","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.98580002784729,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":69,"referenced_works":["https://openalex.org/W38098989","https://openalex.org/W990528835","https://openalex.org/W1494777498","https://openalex.org/W1501924745","https://openalex.org/W1553011341","https://openalex.org/W1580458257","https://openalex.org/W1584774790","https://openalex.org/W1637989849","https://openalex.org/W1677883125","https://openalex.org/W1780440403","https://openalex.org/W1964673167","https://openalex.org/W1972456354","https://openalex.org/W1972535964","https://openalex.org/W1973479349","https://openalex.org/W1976602187","https://openalex.org/W1981458288","https://openalex.org/W1993465897","https://openalex.org/W1996995902","https://openalex.org/W1999206064","https://openalex.org/W2001900724","https://openalex.org/W2002280328","https://openalex.org/W2007495000","https://openalex.org/W2009174342","https://openalex.org/W2013627371","https://openalex.org/W2015522247","https://openalex.org/W2017779103","https://openalex.org/W2021740213","https://openalex.org/W2023791940","https://openalex.org/W2024559246","https://openalex.org/W2028174194","https://openalex.org/W2040721710","https://openalex.org/W2041956586","https://openalex.org/W2050146983","https://openalex.org/W2051268743","https://openalex.org/W2051357459","https://openalex.org/W2056092494","https://openalex.org/W2058581619","https://openalex.org/W2062200995","https://openalex.org/W2072000472","https://openalex.org/W2075481535","https://openalex.org/W2076968916","https://openalex.org/W2078371810","https://openalex.org/W2078992020","https://openalex.org/W2080225612","https://openalex.org/W2080670841","https://openalex.org/W2082856520","https://openalex.org/W2084280842","https://openalex.org/W2088133972","https://openalex.org/W2103440561","https://openalex.org/W2108154994","https://openalex.org/W2109727228","https://openalex.org/W2114205908","https://openalex.org/W2118891894","https://openalex.org/W2126958454","https://openalex.org/W2128401893","https://openalex.org/W2131792847","https://openalex.org/W2132154794","https://openalex.org/W2133631618","https://openalex.org/W2140323904","https://openalex.org/W2144098186","https://openalex.org/W2152864425","https://openalex.org/W2152948641","https://openalex.org/W2161732570","https://openalex.org/W2162807572","https://openalex.org/W2165021720","https://openalex.org/W2170709967","https://openalex.org/W2171526610","https://openalex.org/W4285719527","https://openalex.org/W4321429567"],"related_works":["https://openalex.org/W2387697998","https://openalex.org/W3166605268","https://openalex.org/W2114358369","https://openalex.org/W2154271762","https://openalex.org/W4407744652","https://openalex.org/W1983250356","https://openalex.org/W3036467758","https://openalex.org/W2988412209","https://openalex.org/W2626908878","https://openalex.org/W4242750070"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":7},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":7},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":11},{"year":2018,"cited_by_count":15},{"year":2017,"cited_by_count":9},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":20},{"year":2014,"cited_by_count":11},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}